Shattuck Labs, Inc. (STTK)

What is Shattuck Labs and what does it do?

Shattuck Labs, Inc. is a clinical-stage biotechnology company headquartered in Austin, Texas, with research facilities in Durham, North Carolina, that is developing novel protein therapeutics designed to treat cancer and inflammatory autoimmune diseases. The company’s core insight is that the most potent immune responses come not from blocking a single pathway but from simultaneously dampening immune brakes and pressing immune accelerators — a dual-action approach that distinguishes Shattuck’s lead molecules from conventional checkpoint inhibitors already approved for cancer.

The company went public in August 2020 at a 202 million dollar IPO, trading on NASDAQ under the symbol STTK. Like many clinical-stage biotech firms, Shattuck has no product revenue. Instead, it spends heavily on research and development, running multiple drug trials in parallel, betting that at least one molecule will make it through human testing and eventually receive regulatory approval and market adoption.

What is the ARC platform and why does it matter?

Shattuck’s proprietary technology is called the Agonist Redirected Checkpoint, or ARC, platform. The concept is elegant: most existing cancer immunotherapies block a single immune inhibitor — checkpoint proteins like PD-1 or CTLA-4 that cancer cells exploit to hide from immune attack. But cancer is clever, and checkpoint blockade alone often fails or creates autoimmune side effects. Shattuck’s fusion proteins take a different path. They simultaneously block an immune checkpoint, preventing the cancer’s escape, and activate a separate immune stimulator, amplifying the anti-tumor response. This dual action theoretically offers superior efficacy with a different safety profile than monotherapy.

The ARC platform has produced several development candidates. SL-172154, for example, simultaneously blocks the CD47 checkpoint — a “don’t eat me” signal cancer cells display — while agonizing CD40, a stimulatory receptor that activates immune cells. The combination targets an immune pathway that has shown clinical promise in early human trials.

What is SL-325 and where does it stand clinically?

Shattuck’s most advanced program is SL-325, a Death Receptor 3 (DR3) blocking antibody directed at inflammatory bowel disease and related immune disorders. This molecule does not use the ARC platform but instead targets the DR3-TL1A pathway, which clinical evidence has validated as relevant in Crohn’s disease and ulcerative colitis.

As of mid-2026, the company’s Phase 1 trial of SL-325 in healthy volunteers and IBD patients is nearing completion, with data expected in the second quarter of 2026. If safety and early efficacy signals appear, Shattuck intends to begin a Phase 2 trial in Crohn’s disease patients in the third quarter of 2026. DR3 blocking antibodies have not yet been approved by any regulatory authority, so if SL-325 works, it could be first-in-class — a valuable position if the clinical data supports it. The pathway has attracted interest from larger pharmaceutical competitors as well, so Shattuck faces potential competition if the approach proves successful.

How does Shattuck make money and what is its financial runway?

Like most clinical-stage biotech firms, Shattuck has no operating revenue. The company finances its operations through equity offerings, chiefly via an at-the-market (ATM) program that allows it to sell shares opportunistically when the stock trades at prices management believes are fair. This approach spreads fundraising over time and avoids the dilution of a large, sudden capital raise.

As of December 2025, Shattuck held approximately 78.1 million dollars in cash and short-term investments. By late February 2026, after selling 21.4 million dollars of stock via its ATM offering, cash had risen to 94.5 million dollars. At typical clinical-stage burn rates, ranging from 20 to 30 million dollars annually, this provides roughly three to four years of runway — enough to complete Phase 1 and initiate Phase 2 trials in multiple programs, but not long enough to reach regulatory approval without additional fundraising or a partnership.

What are the main risks facing Shattuck?

Clinical biotech investments carry execution risk: molecules that look promising in laboratory and early animal studies often fail in human trials due to efficacy shortfalls, unexpected toxicities, or manufacturing challenges. Shattuck’s programs are early enough that failure is a material possibility. Additionally, the company faces capital risk — if clinical trials disappoint or burn through cash faster than expected, Shattuck will need to raise more equity at potentially dilutive terms, or curtail programs.

Competitive and regulatory risks are also material. The immunotherapy space is crowded, with large pharmaceutical companies and well-funded startups pursuing similar targets. If competitors reach the market first, or if regulators scrutinize the safety of dual-action fusion proteins, Shattuck’s pathway to approval becomes narrower. Partnership risk is a fourth dimension: Shattuck is small and will likely need to partner with larger firms to fund late-stage trials and commercialize any approved drug, which will reduce the economics the company retains.

How would an investor research this company?

The SEC filings — particularly the 10-K annual report (CIK 0001680367) and quarterly 10-Q filings — provide detailed descriptions of Shattuck’s programs, clinical-trial status, and cash position. The most recent earnings call and prepared remarks walk through upcoming milestones: Phase 1 data readouts, patient enrollment rates in ongoing trials, and any new program initiations or partnerships. The company’s website and press releases announce clinical data presentations at scientific conferences, which provide early signals of efficacy or safety concerns before formal publications.

For investors or analysts tracking clinical biotech, the key metrics to monitor are remaining cash and implied runway, the timeline and readout dates of ongoing trials, and any partnership announcements that might de-risk the company’s path to commercialization. Like all early-stage biotech, Shattuck’s value depends almost entirely on clinical-trial success and the size of market opportunity for any approved drugs — both facts still heavily uncertain at this stage of development.